Suppliers and packagers for generic pharmaceutical drug: ACETYLCYSTEINE

ACETYLCYSTEINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Cumberland Pharms	ACETADOTE	acetylcysteine	INJECTABLE;INTRAVENOUS	021539	NDA AUTHORIZED GENERIC	Padagis US LLC	0574-0805-30	4 VIAL in 1 CARTON (0574-0805-30) / 30 mL in 1 VIAL	2012-12-20
Cumberland Pharms	ACETADOTE	acetylcysteine	INJECTABLE;INTRAVENOUS	021539	NDA	Cumberland Pharmaceuticals Inc.	66220-207-30	4 VIAL in 1 CARTON (66220-207-30) / 30 mL in 1 VIAL	2004-01-23
Eugia Pharma	ACETYLCYSTEINE	acetylcysteine	INJECTABLE;INTRAVENOUS	207358	ANDA	Eugia US LLC	55150-259-30	4 VIAL, SINGLE-DOSE in 1 CARTON (55150-259-30) / 30 mL in 1 VIAL, SINGLE-DOSE	2016-02-29

Acetylcysteine Drug Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the global supply landscape for acetylcysteine, a critical pharmaceutical ingredient used in treating respiratory conditions and as an antidote. The analysis focuses on key manufacturers, production capacities, regulatory compliance, and potential supply chain vulnerabilities.

Who are the Primary Manufacturers of Acetylcysteine?

The global production of acetylcysteine is concentrated among a select group of manufacturers, primarily located in Asia and Europe. These companies possess the chemical synthesis capabilities and meet the stringent quality standards required for pharmaceutical excipients and active pharmaceutical ingredients (APIs).

• N-Acetylcysteine (NAC) API Manufacturers:

  • Hengdian Group Nepharm Co., Ltd. (China): A significant producer with substantial manufacturing capacity. Hengdian Group is a diversified conglomerate with a strong presence in pharmaceuticals.
  • Axplora (formerly IOL Chemicals and Pharmaceuticals Ltd. & Olon S.p.A.) (India/Italy): Following the merger of IOLCP and Olon, Axplora is a key player in the global API market, including acetylcysteine. They operate multiple manufacturing sites across India and Italy.
  • Salix Pharmaceuticals (a Bausch Health Company) (USA): While primarily known as a pharmaceutical company, Salix may have internal or contracted manufacturing capabilities for acetylcysteine, particularly for its branded products.
  • Shanxi Leader Pharmaceutical Co., Ltd. (China): Another prominent Chinese manufacturer contributing to global acetylcysteine supply.
  • Merck KGaA (Germany): A global science and technology company that may produce or supply acetylcysteine through its life science division.
  • Hubei Biocause Pharmaceutical Co., Ltd. (China): A significant contributor to the Chinese API market, including acetylcysteine.

• Excipient-Grade Acetylcysteine Manufacturers:

  • Many API manufacturers also produce excipient-grade acetylcysteine for use in drug formulations. The distinction lies in regulatory filings and specific quality controls.
  • Suppliers catering to the dietary supplement market may also exist, but their products are not suitable for pharmaceutical applications without further validation and regulatory approval.

What are the Production Capacities and Geographic Distribution?

Global production capacity for acetylcysteine is estimated to be in the tens of thousands of metric tons annually. China and India are the dominant manufacturing hubs, benefiting from cost advantages and established chemical industries.

• Geographic Distribution:

  • Asia (China, India): Accounts for the majority of global API production due to lower manufacturing costs, established infrastructure, and a large pool of skilled labor. Companies like Hengdian Group and Axplora (formerly IOLCP) are key players in this region.
  • Europe (Italy, Germany): European manufacturers, such as those within Axplora's network or potentially Merck KGaA, focus on high-quality, compliant production, often serving regulated markets.
  • North America (USA): While some manufacturing may exist, the US is largely a net importer of acetylcysteine APIs, with a focus on finished dosage form manufacturing and formulation.

• Estimated Production Capacity: Precise figures for individual company capacities are often proprietary. However, industry estimates suggest a total global API production capacity well exceeding 20,000 metric tons per year. This capacity is generally sufficient to meet current global demand, with some buffer for fluctuations.

What Regulatory Requirements Must Suppliers Meet?

Suppliers of acetylcysteine for pharmaceutical use must adhere to stringent regulatory requirements established by major health authorities worldwide. This ensures product quality, safety, and efficacy.

• Good Manufacturing Practices (GMP): All manufacturers must comply with GMP standards as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). This covers all aspects of production, including facilities, equipment, personnel, materials, and quality control.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about the manufacturing process, facilities, and controls for a drug substance. Pharmaceutical companies reference these DMFs in their drug applications.
  • U.S. DMFs: Filed with the FDA.
  • European ASMFs (Active Substance Master Files): Equivalent to DMFs in Europe.
• Pharmacopoeia Standards: Acetylcysteine must meet the specifications outlined in major pharmacopoeias:
  • United States Pharmacopeia (USP): Provides standards for identity, strength, quality, and purity.
  • European Pharmacopoeia (Ph. Eur.): Similar standards for the European market.
  • Japanese Pharmacopoeia (JP): Standards for Japan.
  • British Pharmacopoeia (BP): Standards for the UK and other Commonwealth nations.
• Impurity Profiling and Control: Manufacturers must demonstrate robust control over impurities, including process-related impurities and degradation products. This is a critical component of DMF filings and ongoing quality assurance.
• REACH Compliance (Europe): For manufacturers and importers in Europe, compliance with the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation is necessary.

What are the Potential Supply Chain Risks and Mitigation Strategies?

The acetylcysteine supply chain, like many API supply chains, faces potential risks that could disrupt availability.

• Geopolitical Instability and Trade Disputes: Reliance on a few key geographic regions for manufacturing can expose the supply chain to risks from trade wars, sanctions, or regional conflicts.
  • Mitigation: Diversifying supplier base across different geographic regions. Establishing long-term contracts with multiple qualified suppliers.
• Raw Material Availability and Price Volatility: The synthesis of acetylcysteine relies on specific chemical precursors. Disruptions in the supply or significant price fluctuations of these raw materials can impact production costs and availability.
  • Mitigation: Securing multiple sources for key raw materials. Implementing hedging strategies for volatile commodity prices. Maintaining strategic inventory levels of critical precursors.
• Quality Control Failures and Recalls: A single major quality issue from a key supplier can lead to product recalls, regulatory sanctions, and significant shortages.
  • Mitigation: Rigorous supplier qualification and auditing programs. Conducting independent batch testing and quality assessments. Ensuring robust supply chain transparency.
• Natural Disasters and Pandemics: Events like earthquakes, floods, or global health crises can halt manufacturing operations or disrupt logistics.
  • Mitigation: Developing business continuity plans that include alternative manufacturing sites or surge capacity arrangements. Maintaining sufficient safety stock of finished API.
• Regulatory Changes: Evolving regulatory requirements, particularly concerning environmental standards or impurity limits, can necessitate costly process changes for manufacturers.
  • Mitigation: Proactive engagement with regulatory trends and investment in process optimization and analytical capabilities.

How is Acetylcysteine Used in Pharmaceutical Formulations?

Acetylcysteine is a versatile compound with applications in both prescription drugs and over-the-counter (OTC) products. Its chemical properties enable its use as an API and a formulation excipient.

• As an Active Pharmaceutical Ingredient (API):

  • Mucolytic Agent: This is its primary therapeutic use. Acetylcysteine works by breaking disulfide bonds in mucoproteins in respiratory tract secretions, reducing their viscosity. This facilitates expectoration. It is formulated into:
    • Inhalation solutions (nebulizers)
    • Oral powders and granules for reconstitution
    • Effervescent tablets
    • Intravenous solutions (for specific indications)
  • Antidote for Acetaminophen (Paracetamol) Overdose: Acetylcysteine is the gold standard treatment. It replenishes glutathione stores in the liver, which are depleted by acetaminophen metabolites, preventing liver damage. It is administered intravenously or orally.
  • Radiocontrast-Induced Nephropathy Prevention: In some clinical settings, acetylcysteine is used to reduce the risk of kidney damage associated with contrast dye used in medical imaging.

• As an Excipient (Less Common but Potential Use):

  • Antioxidant: Its sulfhydryl group can scavenge free radicals. While primarily used as an API for this property in specific therapies, in some advanced formulations, it might be considered for its antioxidant capabilities to stabilize other components, though this is not a mainstream excipient role.

• Dietary Supplements: Acetylcysteine is also sold as a dietary supplement, often marketed for its antioxidant and liver support properties. The regulatory pathway and quality standards for dietary supplements are distinct from pharmaceuticals.

What is the Market Outlook and Demand for Acetylcysteine?

The market for acetylcysteine is characterized by stable and growing demand driven by its established therapeutic uses and a growing awareness of its potential benefits.

• Market Drivers:
  • Aging Population: Increased prevalence of respiratory diseases such as COPD and chronic bronchitis in aging populations drives demand for mucolytic therapies.
  • Increased Acetaminophen Use: The widespread availability and use of acetaminophen, particularly in combination products, underpins the consistent demand for acetylcysteine as an antidote.
  • Growing Health Awareness: The increasing consumer interest in dietary supplements for antioxidant support and general wellness contributes to demand, particularly in the non-prescription sector.
  • Emerging Research: Ongoing research into new therapeutic applications, such as its role in neurological disorders or as an adjunct in cancer therapy, could open new market segments.
• Market Challenges:
  • Generic Competition: Acetylcysteine is a well-established drug with numerous generic formulations, leading to price pressures and a focus on cost-effective manufacturing.
  • Regulatory Hurdles for New Applications: Developing and gaining approval for novel therapeutic uses for acetylcysteine involves extensive clinical trials and regulatory review.
• Market Size and Growth: The global acetylcysteine market is substantial. While precise figures vary by market research reports, estimates place the market value in the hundreds of millions of USD, with a projected Compound Annual Growth Rate (CAGR) of 3-5% over the next five to seven years. This growth is expected to be consistent rather than explosive, reflecting its mature product status.

Key Takeaways

• The global supply of acetylcysteine API is concentrated among a few key manufacturers, primarily in China and India, with European players contributing to high-quality segments.
• Suppliers must rigorously adhere to GMP, pharmacopoeial standards, and submit DMFs to major regulatory agencies like the FDA and EMA.
• Potential supply chain risks include geopolitical instability, raw material volatility, quality control failures, and disruptions from natural disasters or pandemics.
• Diversification of suppliers, securing raw material sources, and robust quality assurance are critical mitigation strategies.
• Acetylcysteine is primarily used as an API for its mucolytic properties and as an antidote for acetaminophen overdose, with stable and growing market demand.

Frequently Asked Questions

1. What are the key chemical precursors for acetylcysteine synthesis? L-cysteine or its derivatives, and acetic anhydride are primary precursors in the synthesis of acetylcysteine. The specific route can vary between manufacturers.
2. How does the quality of acetylcysteine for pharmaceutical use differ from that used in dietary supplements? Pharmaceutical-grade acetylcysteine must meet stringent USP, Ph. Eur., or JP monograph standards, requiring rigorous impurity profiling and GMP compliance. Dietary supplement grade may have less strict specifications and may not be produced under pharmaceutical GMP.
3. What is the typical shelf life of acetylcysteine API? The typical shelf life for acetylcysteine API, when stored under recommended conditions (e.g., in well-closed containers, protected from light and moisture), is generally between two to five years. Specific shelf life is determined by stability studies.
4. Are there any off-patent, widely available generic acetylcysteine formulations? Yes, acetylcysteine is a well-established compound with numerous generic versions available globally in various dosage forms, including oral powders, effervescent tablets, and inhalation solutions.
5. What is the primary mechanism of action of acetylcysteine as a mucolytic? Acetylcysteine is a mucolytic agent that breaks disulfide bonds within mucoproteins in respiratory secretions. This action reduces the viscosity of mucus, making it easier to clear from the airways.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-master-files

[2] European Medicines Agency. (n.d.). Active substance master file procedure. Retrieved from https://www.ema.europa.eu/en/documents/scientific-guideline/active-substance-master-file-procedure-scientific-guideline_en.pdf

[3] United States Pharmacopeia. (n.d.). USP-NF. Retrieved from https://www.usp.org/products/usp-nf

[4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia (Ph. Eur.). Retrieved from https://www.edqm.eu/en/european-pharmacopoeia-ph-eur

[5] U.S. Environmental Protection Agency. (n.d.). REACH. Retrieved from https://www.epa.gov/chemical-research/reach-regulation